Literature DB >> 31346649

Polypharmacy patterns in the last year of life in patients with dementia.

Rachel Denholm1, Richard Morris2, Rupert Payne2.   

Abstract

PURPOSE: To describe prescribing of medicines in primary care in the last year of life in patients with dementia.
METHOD: A retrospective cohort analysis in UK primary care using routinely collected data from the Clinical Practice Research Datalink. Number of medications and potentially inappropriate medication prescribed one year prior to, and including death, was ascertained.
RESULTS: Dementia patients (n = 6923) aged 86.6 ± 7.3 years (mean ± SD) were prescribed 4.8 ± 4.0 drugs 1 year prior to death, increasing to 5.6 ± 4.0 2 months prior, before falling to 4.9 ± 4.1 at death. One year prior to death, 50% of patients were prescribed a potentially inappropriate medication, falling to 41% at death. Cardiovascular medications were the most common, with decreases in drug count only occurring in the last month prior to death. Prescriptions for gastrointestinal and central nervous system medication increased throughout the year, particularly laxatives/analgaesics, antidepressants and hypnotic/antipsychotics. Women (vs. men) and patients with Alzheimer's (vs. vascular dementia) were prescribed 4.7% (95% CI 2.3%-7%) and 14.6% (11.7-17.3%) fewer medications, respectively. Prescribing decreased with age and increased with additional comorbidities.
CONCLUSIONS: Dementia patients are prescribed high levels of medication, many potentially inappropriate, during their last year of life, with reductions occurring relatively late. Improvements to medication optimisation guidelines are needed to inform decision-making around deprescribing of long-term medications in patients with limited life-expectancy.

Entities:  

Keywords:  Dementia; End-of-life; Inappropriate prescribing; Polypharmacy

Mesh:

Year:  2019        PMID: 31346649     DOI: 10.1007/s00228-019-02721-1

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  26 in total

Review 1.  Managing comorbidities in patients at the end of life.

Authors:  James Stevenson; Amy P Abernethy; Cathy Miller; David C Currow
Journal:  BMJ       Date:  2004-10-16

2.  Polypharmacy and potentially inappropriate medication use among community-dwelling elders with dementia.

Authors:  Denys T Lau; Nathaniel D Mercaldo; Andrew T Harris; Emily Trittschuh; Joseph Shega; Sandra Weintraub
Journal:  Alzheimer Dis Assoc Disord       Date:  2010 Jan-Mar       Impact factor: 2.703

3.  Comorbidity and polypharmacy in people with dementia: insights from a large, population-based cross-sectional analysis of primary care data.

Authors:  Fiona Clague; Stewart W Mercer; Gary McLean; Emma Reynish; Bruce Guthrie
Journal:  Age Ageing       Date:  2017-01-13       Impact factor: 10.668

4.  Daily medication use in nursing home residents with advanced dementia.

Authors:  Jennifer Tjia; Margaret R Rothman; Dan K Kiely; Michele L Shaffer; Holly M Holmes; Greg A Sachs; Susan L Mitchell
Journal:  J Am Geriatr Soc       Date:  2010-04-14       Impact factor: 5.562

5.  Integrating palliative medicine into the care of persons with advanced dementia: identifying appropriate medication use.

Authors:  Holly M Holmes; Greg A Sachs; Joseph W Shega; Gavin W Hougham; Deon Cox Hayley; William Dale
Journal:  J Am Geriatr Soc       Date:  2008-05-12       Impact factor: 5.562

6.  Medication use in nursing home residents with advanced dementia.

Authors:  David M Blass; Betty S Black; Hilary Phillips; Thomas Finucane; Alva Baker; David Loreck; Peter V Rabins
Journal:  Int J Geriatr Psychiatry       Date:  2008-05       Impact factor: 3.485

7.  Inappropriate drugs in elderly patients with severe cognitive impairment: results from the shelter study.

Authors:  Giuseppe Colloca; Matteo Tosato; Davide L Vetrano; Eva Topinkova; Daniela Fialova; Jacob Gindin; Henriëtte G van der Roest; Francesco Landi; Rosa Liperoti; Roberto Bernabei; Graziano Onder
Journal:  PLoS One       Date:  2012-10-03       Impact factor: 3.240

8.  Co-morbidity and drug treatment in Alzheimer's disease. A cross sectional study of participants in the dementia study in northern Norway.

Authors:  Fred Andersen; Matti Viitanen; Dag S Halvorsen; Bjørn Straume; Torgeir A Engstad
Journal:  BMC Geriatr       Date:  2011-10-04       Impact factor: 3.921

9.  Drug treatment at the end of life: an epidemiologic study in nursing homes.

Authors:  Kristian Jansen; Margrethe Aase Schaufel; Sabine Ruths
Journal:  Scand J Prim Health Care       Date:  2014-11-03       Impact factor: 2.581

10.  Association of comorbidity and health service usage among patients with dementia in the UK: a population-based study.

Authors:  Jorge Browne; Duncan A Edwards; Kirsty M Rhodes; D James Brimicombe; Rupert A Payne
Journal:  BMJ Open       Date:  2017-03-09       Impact factor: 2.692

View more
  4 in total

Review 1.  Medication use problems among older adults at a primary care: A narrative of literature review.

Authors:  Christina Christopher; Bhuvan Kc; Sunil Shrestha; Ali Qais Blebil; Deepa Alex; Mohamed Izham Mohamed Ibrahim; Norhasimah Ismail
Journal:  Aging Med (Milton)       Date:  2022-03-15

2.  Clinical and Demographic Profiles of Home Care Patients With Alzheimer's Disease and Related Dementias: Implications for Information Transfer Across Care Settings.

Authors:  Miriam Ryvicker; Yolanda Barrón; Shivani Shah; Stanley M Moore; James M Noble; Kathryn H Bowles; Jacqueline Merrill
Journal:  J Appl Gerontol       Date:  2021-03-20

3.  A delicate balance: Psychotropic polypharmacy and anti-cholinergic use are correlated with fall incidence in Australian inpatients with dementia.

Authors:  Samuel X Tan; Sarah C Cameron; Lit Min Sam; Hugh Eigeland; Karen Hay; Eamonn Eeles; Kannan Natarajan
Journal:  Aging Med (Milton)       Date:  2021-08-27

4.  Psychotropic drug prescription rates in primary care for people with dementia from recorded diagnosis onwards.

Authors:  Karlijn J Joling; Maud Ten Koppel; Hein P J van Hout; Bregje D Onwuteaka-Philipsen; Anneke L Francke; Robert A Verheij; Jos W R Twisk; Rob J van Marum
Journal:  Int J Geriatr Psychiatry       Date:  2020-10-16       Impact factor: 3.485

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.